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Abstract
This report summarizes the symposium, ‘Immunotherapy Biomarkers 2016: Overcoming the Barriers’, which was
held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cosponsored by
the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI), focused on emerging
immunotherapy biomarkers, new technologies, current hurdles to further progress, and recommendations for
advancing the field of biomarker development.
Keywords: Biomarkers, Immunotherapy, Immune monitoring, High throughput, Baseline measures,
Tumor microenvironment

Introduction
Dr. James L. Gulley and Dr. Lisa H. Butterfield opened
the meeting with an introduction. The field of cancer
immunotherapy has enjoyed unprecedented successes
due to positive and durable clinical trial outcomes, the
development of new drugs, biologics and combination
therapies, and the approval of immunotherapeutics such
as immune checkpoint inhibitors. Despite this progress,
the current patient response rates and toxicities associated with immunotherapies have created a sense of urgency to determine which patients would most benefit
from the treatment option. The identification of immune
biomarkers will help to fill knowledge gaps by providing
valuable predictive and prognostic information, and insights on the mechanisms that underlie patient responses or resistance to immunotherapy. This would
allow development of treatment plans specific to each
patient, which could help avoid selection of ineffective
therapies, toxicities, and the resulting need to treat these
toxicities. Furthermore, the rational design of combination therapies only becomes possible once mechanisms
of action and resistance are fully elucidated.
* Correspondence: butterfieldl@upmc.edu
21
Department of Medicine, Surgery and Immunology, University of
Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
Full list of author information is available at the end of the article

Among current hurdles to the identification and development of clinically relevant biomarkers is the lack of
standardized conditions for the collection and storage of
specimens. Indeed, the data obtained from variably
banked specimens are inconsistent, and at present, many
trials bank only non-viable tumor and/or serum samples.
The costs associated with immune assays can also be
prohibitive, as robust and reproducible signals cannot be
obtained by testing small numbers of samples, and attempts to keep costs low by focusing on one or two ‘best
guess’ assays could lead investigators to miss the most
accurate biomarker.
The availability of novel technologies and high
throughput approaches (e.g. mass cytometry, whole exome sequencing, gene expression profiling, TCR diversity, epigenetics, etc.) offers unique opportunities and
challenges for the field of biomarker development.
Through the use of these powerful techniques, a multitude of questions can be addressed with a single sample,
yet the resulting quantity and complexity of data require
unique analytical considerations. The field of immune
monitoring is also influenced by the discovery that metabolic considerations, the microbiome, and signaling
pathway modulation all affect the immune system. Indeed, many standard of care therapies are now known to
operate through immune mechanisms.
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The SITC Biomarkers Task Force was convened to address the current state of the field, and recommend avenues for progress. The ‘Immunotherapy Biomarkers
2016: Overcoming the Barriers’ symposium focused on
outcomes of topics addressed by four Task Force Working Groups. Divided between working groups (WGs),
the following themes were discussed: Immune monitoring, assay standardization and validation (WG1); New
developments in biomarker assays and technologies
(WG2); Systematic assessment of immune regulation
and modulation (high throughput approaches) (WG3);
and Baseline immunity, tumor immune environment
and outcome prediction (WG4). This report summarizes
the outcomes from the meeting.

Immunologic monitoring, assay standardization
and validation (WG1)
WG1 was introduced by Dr. Magdalena Thurin. Putative
biomarkers predictive of response to immunotherapy
must undergo high quality and rigorous validation. As a
result, very few biomarkers are approved as clinically useful. A major hurdle is that immune modulation affects
many cell types and complex interactions while many
drugs and small molecule inhibitors target single proteins
or pathways. Greater understanding of the complexity of
the validation process, especially for markers based on immune response, is needed in order to build up the resources available for immune monitoring. The two
volume white papers from WG1, in which the analytical
and clinical validation process, and regulatory considerations are discussed in depth, have been published [1, 2].
Dr. Alessandra Cesano presented an overview of the
challenges faced in translating biological data into predictive biomarkers and described the example of Prosigna as a cleared diagnostic. A combination of factors
from the host, cancer cells, and tumor microenvironment (TME), including the microbiome, shape interactions between the tumor and the immune system. This
presents various hurdles, the first being the complexity
of integrating these interactions with an informative analyte (DNA, RNA, and proteins) to yield a multivariate,
multi-analyte assay. Although tens of thousands of
markers in the GVK Biosciences (GVK Bio) Online Clinical Biomarker Database (GOBIOM) developed in collaboration with the U.S. Food and Drug Administration
(FDA) have been identified, only a fraction of these have
been developed into validated genomic biomarkers for
FDA-approved drugs, and none have become multiplex,
in vitro companion diagnostics. For a predictive biomarker to be applied in the clinic, it must have analytic
(the ability to accurately and reliably measure analytes of
interest in clinical specimens representative of the target
population) and clinical validity, in addition to clinical
utility. Multiple organizations have published guidelines
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for the validation of diagnostic tests, with recommendations regarding analytic sensitivity, specificity, reproducibility, and assay robustness [3, 4]. Dr. Cesano suggested
that the co-development of drugs and companion diagnostics could address the biomarker deficiency. Although such an approach would increase the complexity
of drug development, it may make the process more successful, and has great potential value for patients and
health system resource utilization.
Dr. Ilan Kirsch detailed the capabilities of highthroughput PCR-based sequencing technology for T cell
receptor (TCR) clonality assessment. The basis of this
technology arose from the fact that the genes that encode functional immune receptors initially exist in germline DNA as a number of discrete, non-contiguous
segments (variable, V, diversity, D, and joining, J). As a
prerequisite to the formation of a functional immune receptor, a site-specific DNA breakage and rejoining event
occurs that unifies any combination of these segments
into a contiguous V(D)J region, which encodes the hypervariable part of the immune receptor. The assay uses
forward primers from the V segments, and reverse
primers from the J segments, to amplify and then sequence the area of this rearrangement event, thus creating a unique “barcode” of the lymphocyte and all clonal
progeny of the rearranged cell. In this way, immunosequencing can quantify and specify every B and/or T cell
in a sample of interest with a high degree of sensitivity
and reproducibility. The superior accuracy of immunosequencing has been demonstrated in side-by-side comparisons with multi-parameter flow cytometry, in which
immunosequencing successfully detected minimal residual disease in samples from patients with both T and
B cell hematologic malignancies that were missed by
flow cytometric techniques [5]. Additional applications
of high-throughput clonality assessment include insights
into drug mechanisms, measurements of immune system dynamics, and prognostic potential. In a study using
immunosequencing to assess the number and clonality
of tumor-infiltrating lymphocytes (TIL) from tissue samples of stage II DNA mismatch repair-proficient colon
cancer patients, it was found that patients with belowmedian clonality and TIL number were at higher risk for
disease recurrence [6]. This type of TIL assessment also
may predict response to therapy. When applied to the
setting of melanoma, patient samples with TIL beneath
the median number and level of clonality were less likely
to respond to anti-PD-1 therapy [7].
Dr. Sylvia Janetzki discussed challenges associated with
single cell functional immune assay validation. The inherent variability associated with assays such as ELISPOT and
intracellular cytokine staining [8], due to either the assay itself or due to the sample, needs to be considered. Sample
quality must be addressed in pre-analytical validation and
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many guidelines already exist regarding peripheral blood
mononuclear cell (PBMC) processing [9], avoidance of
granulocyte contamination, apoptosis assessment, and overnight resting of samples. Assay variability arises from the
lack of standardized protocols as well as the absence of a
“gold standard”, which makes accuracy impossible to determine. To address the issue of assay variability, participation
in proficiency panels [10] is recommended, as they provide
an analysis of one’s own measurement in relation to
measurements from many other groups in the field using
many different protocols. Open proficiency panel programs
already exist for ELISPOT and multimer panels and are
available to all labs on a non-profit basis. In addition to
evaluating the relative accuracy of data, proficiency panels
can be used to identify critical protocol variables that are
predictive of assay performance. These critical variables
have been collected and summarized in published
harmonization guidelines to be used by labs for
optimization of assay outcomes [11], and are now available
for ELISPOT assay and analysis, multimer staining, intracellular cytokine staining (ICS) assay, and gating. Finally, as
precision is the most important parameter to ensure confidence in data analysis, intra-assay, inter-assay, and interoperator precision need to be demonstrated in the form of
repeatable results with a low false positive rate once assays
have been harmonized.
Dr. Shyam Kalavar from the U.S. FDA presented on regulatory considerations for in vitro diagnostic devices in cancer immunotherapy. Companion in vitro diagnostic (IVD)
devices provide information that is essential for the safe
and effective use of a corresponding therapeutic product
(e.g. PD-L1 IHC 22C3 pharmDx diagnostic test manufactured by Dako A/S (now Agilent Technologies)). In contrast, complementary diagnostics are tests that identify a
biomarker-defined subset of patients that is expected to respond particularly well to a drug, and aid risk/benefit assessments for individual patients, but are not pre-requisites
for receiving the drug (i.e., are not companion diagnostics).
An example of a complementary IVD device is PD-L1 IHC
28–8, manufactured by Dako A/S (now Agilent Technologies) for non-squamous NSCLC and melanoma. As
commercialization of IVD requires FDA clearance, a key
regulatory question is whether adequate analytical and clinical performance data are available to be approved contemporaneously with the drug approval. In the case of
immunohistochemistry-based assays such as PD-L1 IHC
22C3, analytical validation studies include biochemical
characterization of the antibody, tests of assay sensitivity
and specificity, precision, inter-laboratory reproducibility,
assay robustness, the impact of pre-analytical variables, stability, and control cell line validation. Additional information regarding IVD regulation is available in guidance
documents provided by the FDA to help direct validation
of such devices.
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Each section of the meeting had time for a panel discussion. The speakers addressed several questions, including those relating to publication of assay details for
proper evaluation by the field.

New developments in biomarker assays and new
technologies (WG2)
Dr. Jianda Yuan introduced the WG2 areas of focus. Over
the past year, the members of Biomarkers WG2 have collaborated to evaluate new technologies. These include
quantitative real-time PCR-assisted cell counting (qPACC)
[12], protein microarray (‘seromics’) [13], flow and mass
cytometry [14], multiplexed tissue biomarker imaging
[15], and whole exome sequencing for mutation load/
neoantigen discovery [16]. All the resulting papers have
been published in the Journal for ImmunoTherapy of
Cancer (JITC) technology primer series [17–23], with still
more on the horizon. Additionally, the WG2 white paper
highlights novel technologies and emerging biomarkers
relevant to individualized cancer immunotherapy, with
recommendations for best practices unique to each [24].
As the prognostic power of TILs continues to gain widespread recognition [25, 26], Dr. Bernard A. Fox believes
that multispectral imaging is critical to advancing our understanding of the complex interactions in the TME.
Using markers of immune cell subsets, phenotype, and
function [27], standardized multispectral immunohistochemistry is ideally suited to address interactions between
multiple parameters, especially when patient sample availability is a consideration. However, difficulties associated
with this technique include high background fluorescence,
availability of antibodies, photobleaching, and image
analysis [28]. The development of a tyramide signal amplification reagent was a breakthrough in multispectral technology that obviates such issues. This technique was used
to interrogate tumors from a cohort of patients with melanoma to determine that the CD8:FoxP3 ratio predicts
ability to generate TIL, the predictive power for which increases with the addition of PD-L1 [29]. The examination
of multiple parameters thus offers value compared to single parameter analysis in a complex environment where
ratios, relative positions, and functional analyses are
mechanistically important. Dr. Fox suggested that advancements in multispectral imaging technology could
provide support for stratification of patients for clinical
trials in the future.
Dr. Jianda Yuan described how next-generation sequencing technologies such as whole exome sequencing are paving the way for precision oncology. Mutation-derived
antigens (neoantigens) have long been an area of research
interest, but the patient-specific nature of neoantigens represented a hurdle to the broader application of these data
for a therapeutic purpose. The advent of whole exome sequencing has allowed for a comprehensive description of
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the mutation load, termed the “mutational landscape”,
which has been a valuable resource to the field of immunotherapy, since neoantigen immunogenicity has been shown
to be a correlate of response to treatment. For example,
neoantigen-specific T cell reactivity was demonstrated via
tumor exome sequencing in ipilimumab-responsive melanoma [30], and most patients who responded to ipilimumab
treatment had a relatively high mutation load [31]. Similarly, the nonsynonymous mutation burden was associated
with clinical benefit of anti-PD-1 therapy in patients with
NSCLC [32], and MMR deficiency in colorectal cancer correlated with better clinical response to PD-1 blockade [33].
Potential uses of whole exome sequencing for neoantigen
discovery and precision oncology include: prediction of
patient response to vaccine and cancer immunotherapy,
identification of new targets, therapeutic neoantigen vaccination, adaptive neoantigen T cell transfer therapy, and the
design of effective combination immunotherapies. Strategies to move the field forward include combining approaches that integrate function (e.g. ELISPOT), phenotype
(e.g. multicolor flow cytometry), and signature (e.g. whole
exome sequencing, gene expression profile).
Dr. Holden Maecker spoke of the need to systematically
measure immunocompetence in cancer patients, as traditional radiation and chemotherapy can be immunosuppressive, and immunotherapeutic agents interact directly
with the immune system. Such an assessment of circulating immune subsets and functions could be prognostic of
an overall response or a response to specific agents [34].
Mass cytometry (CyTOF) is a powerful alternative to
fluorescence flow cytometry that can simultaneously assess multiple parameters with little to no spillover between channels. Dr. Maecker described two studies that
employed the use of CyTOF technology to interrogate the
immune systems of cancer patients at various time points,
both of which suggested that specific immune profiles
may be prognostic for response to immunotherapy. In
particular, the presence of CD8+ central memory T cells
and/or IL-2-producing T cells were associated with response to treatment. This immune profile may be a common predictor across multiple chronic conditions, as lack
of CD8+ T cells that make IL-2 has been associated with
disease progression in HIV [35]. The mTOR pathway
might represent a means of boosting the central memory
compartment in order to improve response rates for immunotherapies, as mTOR inhibition has been shown to
reduce PD-1 expression and increase central memory T
cells [36, 37].
Multifaceted immunomonitoring techniques to identify
biomarkers predictive of clinical outcome were addressed
by Dr. Cristina Maccalli. To capture the complexity of
tumor-immune cell interactions, a multifaceted approach
integrates different techniques for assessing immune
cell phenotypes, functional capabilities, and negative
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immunoregulatory factors within the same patient sample.
Such an approach was applied in a multicenter, controlled
study of patients with melanoma being treated with an
anti-CTLA-4 agent plus chemotherapy [38, 39]. Initially,
standardized multiparameter flow cytometry was used for
phenotype analysis of peripheral blood mononuclear cells
(PBMC) to identify different subsets of T cells, NK cells,
and B cells both at baseline and treatment. Soluble serum
factors such as secreted natural killer group 2D (NKG2D)
receptor ligands, which are upregulated in tumor cells and
can impair T cell responses were also measured. These
data were integrated with classification and regression
trees (CART) and an interesting finding emerged, in
which patients with longer overall survival were lacking
the soluble ligand and had an increase in the frequency of
CD4+ BTLA+ memory T cells and Th17-like cells at baseline. Further investigation with functional assays revealed
a correlation between antigen-specific T cell responses
and clinical outcomes [40]. Thus, multifaceted immunomonitoring platforms can help identify a functional immunological signature predictive of clinical outcome to
immunotherapy, although this platform needs to be optimized and validated with a large cohort of patients undergoing immunotherapy treatments. Dr. Maccalli concluded
by stating that the contemporaneous analysis of tumor
and peripheral blood could define whether i) a specific
tumor immunophenotype is characterized by a distinct
peripheral blood gene signature and ii) those signatures
correlate with clinical outcome. If it proves that gene signatures correlate with a peripheral blood cell subset
phenotype, this would allow a detailed characterization of
specific immunophenotype associated with patients’ clinical outcome.
The WG2 section had a panel discussion with the
speakers. Topics discussed included the timing of sample
testing, analysis of primary tumors and metastases, and
the extent to which technologies and approaches can be
prioritized based on existing data.

Assessment of immune regulation and
modulation systematically (high throughput
approaches) (WG3)
Dr. David F. Stroncek presented the areas focused on by
the third WG. WG3 sought to provide guidance on which
tissue sources should be considered for analysis and monitoring during the process of clinical trial design. Sample
materials discussed included serum/plasma, peripheral
blood leukocytes, and the microbiome (a focus of the WG3
white paper). In addition, the means by which the tissue
should be evaluated, such as proteomics, flow cytometry,
gene expression, micro RNA expression, and mutation analysis approaches were considered, along with recommendations for data analysis. Adoptive cell therapies were also
discussed. The rapid evolution of the science, and of
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analytical methods, as well as the very large quantities of
data involved, present challenges to developing state-ofthe-art guidance [41].
Dr. Peter P. Lee focused on three main aspects of the
tumor microenvironment: 1) the importance of the tumor
microenvironment to clinical outcomes, 2) the equal importance of the number of cells present and the spatial relationships between them, and 3) the tumor-draining
lymph nodes (TDLN), which are the major site of cancer
cell-immune cell interaction. Tumors comprise more than
cancer cells alone, since roughly 50% of human tumors
are >50% stroma. Patients with ‘stroma-rich’ tumors have
poorer clinical outcomes because stromal cells provide
growth and metabolic factors that protect cancer cells
from a variety of anti-cancer drugs, including chemotherapeutic agents and targeted drugs such as BRAF inhibitors.
Indeed, stromal cell density appears to be an independent
prognostic marker in breast, colorectal, pancreatic, and
other cancers. As mentioned by other presenters, intratumoral immune cells are also predictive of clinical outcome, which led to the Immunoscore effort [42] to aid in
clinical decision-making. The interplay between cancer
cells, immune cells, and non-immune stromal cells within
the TME can be studied using an automated quantitative
pathology imaging system. This system allows for the
identification of spatial immune cell patterns within the
tumor, which may have implications for clinical outcomes.
For example, to address whether TDLN functionality is altered in cancer, immune cell populations were evaluated
in disease-free versus relapsed breast cancer patients. A
significantly higher percentage of CD4+ T cells and CD1a
+ dendritic cells (DC) was found in the draining lymph
nodes of patients who remained disease-free versus those
who had relapsed, and this immune profile alone correlated with disease-free survival [43]. Spatially, DC within
lymph nodes of disease-free patients were found in clusters, whereas the architecture of DC clusters from the
nodes of patients whose disease had relapsed were disrupted —a pattern that also correlated with clinical outcome [44]. Quantitative, spatial image analysis of tumors
and TDLN will be highly informative in understanding
how therapies modulate the balance between cancer and
host immune responses.
The importance of monitoring adoptive cellular therapies as a means of improving clinical outcomes for patients
was presented by Dr. David F. Stroncek. Multiple studies
of tumor-infiltrating lymphocytes (TIL) as sources of autologous cells for transfer in patients with melanoma have
yielded markers indicative of clinical outcome. Specifically,
higher total numbers and percent of CD8+ T cells infused
are associated with improved outcomes, as is persistence
of T cell clones post-infusion. Other markers have been
correlated with outcomes in individual studies and may
merit additional investigation, such as telomere length
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and expression of CD27 [45]. Studies of CD19 CAR T cells
in patients with lymphoma or acute lymphocytic leukemia
(ALL) have demonstrated that peak levels of CAR T cells
with a high CD8:CD4 T cell ratio, and higher numbers of
CD8+ effector T cells, are associated with a better response [46–48]. Factors that influence high peak blood
levels of CD19 CAR T cells include the presence of CD19
+ cells at the time of infusion (lymphoma) [47] and quantities of blasts in bone marrow (ALL). Dr. Stroncek also
commented on three complications associated with adoptive cellular therapies: tumor lysis syndrome, cytokine release syndrome (CRS), and neurotoxicity, and the use of
biomarkers to assess them. Patients with a higher tumor
burden and greater numbers of circulating CAR T cells
are more likely to experience CRS [46]. In the clinic, elevated levels of IFNγ and IL-6, or C-reactive protein (CRP)
as a surrogate for IL-6, can be tested for, as markers of
toxicity [46]. Closing recommendations focused on
monitoring levels of adoptively transferred cells; analyzing
infused cells for phenotype, gene expression, and polymorphisms; and tracking CRP levels post-treatment.
Dr. Barbara Seliger opened the discussion about
immune monitoring of clinical trials by noting that the
primary goal of cancer immunotherapy is to increase antitumor activity by activating the immune response, altering
the tumor microenvironment, and overcoming tumorassociated barriers. In order to analyze the efficacy of
these strategies, it is necessary to integrate multiple highthroughput technologies, which requires investigators to
obtain patient samples of peripheral blood, tumor cells,
and tumor-infiltrating cells. Ideally, samples should be collected prior to, during, and after treatment, depending on
the type of immunotherapy used. Although such an approach is best suited for peripheral blood and in the setting of melanoma, the discovery of links between the
immune response and the expression of immune modulatory molecules on tumors may present alternative approaches to monitoring. For example, a decrease in tumor
antigen expression is associated with a lack of tumorspecific immune response, and alterations in class I antigen presentation can lead to reduced effector cell cytotoxicity. [49]. It is also important to note that certain types of
immunotherapy, including peptide vaccination, checkpoint inhibitors, and adoptive T cell transfer, have been
shown to allow for the evolution of acquired resistance to
treatment by selecting for HLA class I loss variants. HLAG is a non-classical HLA class I molecule that is a putative
novel inhibitory checkpoint, as it is often over-expressed
in tumors, can inhibit NK and T cell mediated cytotoxicity, and is associated with poorer prognoses in a variety
of solid tumors [50]. Dr. Seliger closed by saying that it is
important to understand the mechanisms of immune escape in order to appropriately apply immunomodulatory
agents, but immune monitoring should not cease once a
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therapy has been selected. Rather, continued monitoring
is an important means of addressing resistance to treatment that may emerge over time.
Ms. Janet Siebert described the current state of immune
monitoring as a compilation of “humpty dumpty data
sets” in her presentation on Analysis of the Systemic Host
Response. Her statement emphasized that contemporary
data sets are generated through interrogation of multiple
tissues, using multiple assays, from multiple organizations
(from multiple intra- or inter-institutional cores), across
academia, industry, and government. Such fragmentation
could reduce the feasibility of measuring of the systemic
response. Instead, the field needs to move toward the
compilation of integrated heterogeneous data sets or “het
sets”, which use a consistent assay-agnostic format that
spans assays, tissues, and organizations, and supports
analysis of the systemic cross-compartment response. Advantages of het sets include a common technical and conceptual representation of an otherwise unwieldy data set,
the application of the same analytical tools to a large number of analytes from different assays, and the ability to
apply established multivariable analytical approaches to
the integrated whole. Ideally, these analytical approaches
would be well-established and magnitude-insensitive with
both visual and quantitative results that can be easily validated in follow-up studies. Decision tree classification is
an example of a suitable analytical approach that seeks to
determine which analytes most cleanly separate patients
into responder and non-responder groups. These can be
supplemented with reference data sets to ensure that
thresholds are not arbitrary or over-fitted. To address systemic responses that span assays or tissues, linear regression modeling can be used to capture the relationship
between analyte pairs [51]. The resulting complex immunological data can then be synthesized with a network
arc diagram to provide succinct visualization, and insights
into underlying the biological mechanisms of interest,
such as responsiveness to therapy [52].
During the WG3 panel discussion, the speakers commented on the use of high throughput technologies to
test adoptive cellular therapies, and detection of tertiary
lymphoid structures.

Prediction of clinical outcome based on baseline
measures (WG4)
Dr. Sacha Gnjatic introduced the fourth WG and its activities. Aiming to provide recommendations on how to
predict a patient’s response to treatment through analysis of baseline biomarkers in blood and tumor, including MDSC and other immature myeloid cells, and
checkpoint molecule expression. WG4 also focused on
the diversity of immune cells present in the TME (including tertiary lymphoid structures), effectiveness of
peripheral surrogates of the TME, and new technologies
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to aid in the comprehensive analysis of baseline immunity (manuscript in revision for the Journal for ImmunoTherapy of Cancer).
Investigations into the tumor microenvironment at a
genetic level, as presented by Dr. Samir N. Khleif, seek to
address whether genetic changes within the tumor microenvironment can guide the design of cancer immunotherapeutics. The power of this approach was illustrated by
investigations into Ras as a mutated antigen immune target. In contrast to prognostic or predictive biomarkers,
immune targets are biomarkers that might not correlate
strongly with response to treatment, such as PD-L1, but
can help direct the development of therapies. Dr. Khleif
described a study in which Ras mutations were used as
immune target biomarkers. Patients with advanced solid
tumors bearing Ras mutations were given a cancer vaccine
comprised of autologous peptides along with IL-2, GMCSF, or both. Although most patients developed antigenspecific immune responses, only one patient out of 57
generated productive immunity that went on to eliminate
the tumor cells [53]. This disparity led to the discovery
that regulatory T cell (Tregs) are significantly expanded in
colon cancer patients with mutated Ras compared to both
healthy individuals and colon cancer patients with wildtype Ras. It was found that mutant Ras activates the MEKERK-AP1 pathway to induce secretion of high levels of IL10 and TGF-β1, which generate local induction of regulatory T cells (Treg) in the tumor microenvironment [54].
Ras mutation was noted to be an early event in the development of tumors leading to the proliferation of affected
cells, and the resulting induction of Treg serves to support
tumor immune escape by creating a suppressive microenvironment that inhibits the anti-tumor immune response. Dr. Khleif suggested that an additional agent
targeting Treg could boost the efficacy of a cancer vaccine
in patients with Ras mutations. Thus mutated antigens
used as immune target biomarkers can also guide investigations into immune bystander effects on the microenvironment, with the potential to inform the development of
rational combination treatments.
In a forward-looking discussion, Dr. Vaios Karanikas presented on multiplex immunohistochemistry (IHC) in clinically annotated material: where are we and where are we
going? As more clinical data become available from patients
treated with cancer immunotherapies, it has become clear
that patients with inflamed tumors are more likely to respond to treatment. A deeper understanding of the interactions between the immune system and tumor cells within
the tumor microenvironment is needed to achieve the ultimate goal of designing therapeutic strategies capable of inflaming “cold” tumors and addressing immune escape
mechanisms. The identification of predictive and prognostic biomarkers using high throughput approaches like
multiplex IHC would aid this endeavor and Dr. Karanikas
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offered a number of best practices for consideration. As
tumor cells do not develop in isolation, it is imperative to
assess the TME comprehensively (immune cells, stroma,
and tumor cells), and compare paired samples from the
same patient before, during, and after treatment. Choice of
technology, e.g., chromogenic vs immunofluorescence, and
antibody selection, can be guided by pragmatism. A relevant example of the complex questions that can be addressed by multiplex IHC includes the efforts to define the
tumor-infiltrating cell types. This approach demonstrated
the prognostic value of specific subsets of immune cell infiltrates [55, 56], their spatial distribution within the TME
[57, 58], and qualitative characteristics such as an exhausted
phenotype [7, 59]. Importantly, the integration of complementary technologies such as multiplex IHC, mutational
profiling, and gene expression patterns can overcome the
limitations of each method, as well as offer an improved
understanding of the TME toward the identification of predictive and prognostic immune biomarkers.
The identification of biomarkers in the peripheral blood
– the most readily available tissue for sampling – to assess
a patient’s response to treatment was the focus of Dr.
Marcus O. Butler’s Multiplex/Blood Profiles presentation.
Central to this approach is a need to identify whether biomarkers in the TME are also present in the peripheral
blood. Investigations into circulating PD-1+ lymphocytes,
which have been shown to contain T cells specific for
tumor-associated antigens and neoantigens, have provided
evidence to suggest that this is possible, although such
populations of interest are less frequent in blood [60]. The
main tools available to interrogate rare cell populations include flow and mass cytometry and a number of different
computational methodologies have been published to
guide the analysis of these complex data [61]. In addition
to its utility as a window into the TME, the peripheral
compartment can be used to try to influence baseline immunity. One such study involved the adoptive transfer of
in vitro-activated tumor antigen-specific T cells into patients with metastatic melanoma, the result of which was
a stable increase in anti-tumor central memory cells detectable in the peripheral blood [62]. Upon subsequent
treatment with anti-CTLA-4, the transferred cells expanded and generated partial responses [62] that laid the
foundation for follow up studies including Adoptive Cell
Therapy InVigorated to Augment Tumor Eradication
(ACTIVATE): Cohorts 1–3.
In a discussion about B cells at the tumor site, and systemic humoral responses, as predictive biomarkers, Dr.
Sacha Gnjatic noted that B cells organized in tertiary
lymphoid structures (TLS) can be identified near tumors
and the presence of dense follicular B cells along with mature DC is associated with a good prognosis in non-small
cell lung cancer (NSCLC) [63]. Taking these observations a
step further, investigators sought to determine whether the
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specificity of local and circulating antibodies may reflect the
immunogenicity of the tumor. Tumor antigen-specific
humoral immunity has been previously shown to correlate
with CD4+ and CD8+ T cell responses to the cancer-testis
antigen NY-ESO-1 [64, 65], and more recent studies in patients with NSCLC have gone on to demonstrate correlations between anti-NY-ESO-1 antibody titers and tumor
stage, overall survival, and clinical course following antiCTLA-4 immunotherapy [66, 67]. To translate humoral
immune monitoring to the clinic, a seromics approach
would allow for a sensitive and high-throughput means of
detecting alterations in the antibody repertoire as a surrogate for the tumor immune response. Additional work in
the area of comprehensive immune monitoring will need to
establish appropriate targets that assign functionality to
antigen specificity and relate to clinical outcomes.
The WG4 panel discussion addressed issues of tumor
acquisition, including cost, logistics, and enabling a culture of routine tissue banking at different institutions
and clinical settings.

National cancer institute perspectives on
biomarkers
In a presentation focused on lessons learned from the peripheral immunoscore, Dr. Jeffrey Schlom, discussed applications for the current state of flow-based technology that
now allows for identification of 123 immune cell subsets
from one tube of blood, using 30 markers. The subsets analyzed include nine standard immune cell subsets and 118
additional subsets relating to maturation and function
[68]. In particular, monitoring of multiple peripheral immune subsets can aid in the identification of patients most
likely to benefit from immunotherapy. For example, one
study of patients with metastatic breast cancer treated
with chemotherapy alone or in combination with cancer
vaccine sought to use baseline measures of peripheral immunity to discriminate between patients with longer or
shorter PFS. Indeed, a correlation between the presence of
particular immune cells at baseline and disease progression was noted, although only in the combination therapy
arm [69]. Such peripheral immunoscore analyses are
intended to complement biopsy analyses, and can be used
in many cancer types and stages for which biopsies are
not easily obtained. Peripheral immune monitoring can
extend beyond cells to the level of antigens. Several studies have demonstrated improved clinical outcomes due to
the presence of cascade antigens (epitope spreading) following treatment with cancer vaccines as a result of tumor
cell lysis and subsequent cross-priming [70–74]. For example, a trial using the cancer vaccine PROSTVAC in patients with prostate cancer revealed that a majority of
patients generated T cells that mounted an immune response to antigens not present in the vaccine [75]. These
data indicate a means by which heterogeneity among
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tumor cells can be minimized therapeutically, and Dr.
Schlom suggested that all cancer vaccine clinical trials
should include cascade antigen analyses.
Dr. Jay A. Berzofsky discussed the utility of extracellular
vesicles (EV) as biomarkers of immune responses and
tumor responses in cancer immunotherapy. Although previously underestimated as a homogeneous population, EV
are gaining interest as diverse subsets that play many immunoregulatory roles in cancer. Released by both immune
cells and tumor cells, EV are 100 nm particles capable of
shuttling “packets” of information in the form of mRNA,
miRNA, and protein between cells, the effects of which
can be immunostimulatory or immunosuppressive. Similar to standard FACS technology, nanoFACS was developed to analyze, sort, and decode EV subsets based on
light scatter and fluorescence. Once sorted, the EV could
be further analyzed by molecular profiling via protein expression and RNA/DNA typing. The analysis of EV from
patient plasma samples could provide a means of
monitoring the immune response and directing treatment
decisions, and it has the potential to make both
membrane-bound and soluble (exosome-bound) TMEspecific biomarkers accessible via “liquid biopsy”.

Conclusions
In his closing remarks, Dr. James L. Gulley was optimistic
that the opportunities presented by the use of biomarkers
for immune monitoring outweighed current challenges.
Having raised awareness of potential difficulties in immune biomarker research, the SITC Biomarkers Task
Force WGs have also made recommendations for how to
approach these challenges, and will continue to provide
guidance as the field develops.
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